NCT06487663View on ClinicalTrials.gov

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

October 27, 2025

Study Completion Date

October 27, 2026

Conditions
Hepatocellular Carcinoma Non-resectableCholangiocarcinoma Non-resectableLiver MetastasesLiver Malignant Tumors
Interventions
PROCEDURE

TACE with ICI

Transcatheter hepatic artery chemoembolization and immune checkpoint inhibitors

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER